An Open Label Study to Evaluate the Pharmacokinetics, Safety, Tolerability and Efficacy of Deferasirox Administered to Chinese Patients With β-thalassemia Major Aged From 2 to Less Than 6 Years Old
PHASE4WithdrawnINTERVENTIONAL
0
Timeline
Start Date
June 30, 2013
Primary Completion Date
April 30, 2014
Study Completion Date
October 31, 2014
Conditions
β-thalassemia Major
Interventions
DRUG
Deferasirox
Patients will start their deferasirox treatment with a dose of 20 mg/kg/day.